Open AccessUse of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes (hiPSC‐CMs) to Monitor Compound Effects on Cardiac Myocyte Signaling Pathways
Author(s) -
Guo Liang,
Eldridge Sandy,
Furniss Mike,
Mussio Jodie,
Davis Myrtle
Publication year - 2015
Publication title -
current protocols in chemical biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.503
H-Index - 14
ISSN - 2160-4762
DOI - 10.1002/9780470559277.ch150035
Subject(s) - induced pluripotent stem cell , cardiotoxicity , signal transduction , myocyte , microbiology and biotechnology , function (biology) , drug discovery , cardiac myocyte , biology , biological pathway , pharmacology , computational biology , bioinformatics , embryonic stem cell , biochemistry , gene expression , genetics , chemotherapy , gene
There is a need to develop mechanism‐based assays to better inform risk of cardiotoxicity. Human induced pluripotent stem cell–derived cardiomyocytes (hiPSC‐CMs) are rapidly gaining acceptance as a biologically relevant in vitro model for use in drug discovery and cardiotoxicity screens. Utilization of hiPSC‐CMs for mechanistic investigations would benefit from confirmation of the expression and activity of cellular pathways that are known to regulate cardiac myocyte viability and function. This unit describes an approach to demonstrate the presence and function of signaling pathways in hiPSC‐CMs and the effects of treatments on these pathways. We present a workflow that employs protocols to demonstrate protein expression and functional integrity of signaling pathway(s) of interest and to characterize biological consequences of signaling modulation. These protocols utilize a unique combination of structural, functional, and biochemical endpoints to interrogate compound effects on cardiomyocytes. © 2015 by John Wiley & Sons, Inc.